These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 18656197)
81. The endothelium in compliance and resistance vessels. Triggle CR; Ding H Front Biosci (Schol Ed); 2011 Jan; 3(2):730-44. PubMed ID: 21196408 [TBL] [Abstract][Full Text] [Related]
82. [Nitric oxide (NO), vascular protection factor. NO related cardiovascular diseases]. Tiritilli A Presse Med; 1998 Jun; 27(21):1065-70. PubMed ID: 9767831 [TBL] [Abstract][Full Text] [Related]
83. [Vascular endothelium as a factor in information transfer between the cardiovascular and immune systems]. Stvrtinová V; Ferencík M; Hulín I; Jahnová E Bratisl Lek Listy; 1998 Jan; 99(1):5-19. PubMed ID: 9588073 [TBL] [Abstract][Full Text] [Related]
84. EDHF -- are there gaps in the pathway? Edwards G; Weston AH J Physiol; 2001 Mar; 531(Pt 2):299. PubMed ID: 11310433 [No Abstract] [Full Text] [Related]
85. Endothelium-derived hyperpolarizing factor and vascular function. Ozkor MA; Quyyumi AA Cardiol Res Pract; 2011; 2011():156146. PubMed ID: 21876822 [TBL] [Abstract][Full Text] [Related]
86. Evidence against C-type natriuretic peptide as an arterial 'EDHF'. Garland CJ; Dora KA Br J Pharmacol; 2008 Jan; 153(1):4-5. PubMed ID: 17965742 [TBL] [Abstract][Full Text] [Related]
87. Gender and the endothelium. Kublickiene K; Luksha L Pharmacol Rep; 2008; 60(1):49-60. PubMed ID: 18276985 [TBL] [Abstract][Full Text] [Related]
88. Early markers of cardiovascular disease. Kapuku GK; Harshfield GA; Davis HC; Treiber FA Vascul Pharmacol; 2006 Nov; 45(5):277-80. PubMed ID: 17011834 [TBL] [Abstract][Full Text] [Related]
89. What is new in endothelium-derived hyperpolarizing factors? Campbell WB; Gauthier KM Curr Opin Nephrol Hypertens; 2002 Mar; 11(2):177-83. PubMed ID: 11856910 [TBL] [Abstract][Full Text] [Related]
90. Endothelium-derived hyperpolarizing factor and diabetes. Gao X; Martinez-Lemus LA; Zhang C World J Cardiol; 2011 Jan; 3(1):25-31. PubMed ID: 21286215 [TBL] [Abstract][Full Text] [Related]
91. Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium. Taylor SG; Weston AH Trends Pharmacol Sci; 1988 Aug; 9(8):272-4. PubMed ID: 3074543 [No Abstract] [Full Text] [Related]
92. Endothelium-derived hyperpolarizing factor in the brain: influence of sex, vessel size and disease state. Davis CM; Siler DA; Alkayed NJ Womens Health (Lond); 2011 May; 7(3):293-303. PubMed ID: 21612351 [TBL] [Abstract][Full Text] [Related]
93. Focus on vascular pharmacology. Doggrell SA Drug News Perspect; 2004 Oct; 17(8):543-52. PubMed ID: 15605115 [TBL] [Abstract][Full Text] [Related]
94. Vascular Aging: Implications for Cardiovascular Disease and Therapy. Ghebre YT; Yakubov E; Wong WT; Krishnamurthy P; Sayed N; Sikora AG; Bonnen MD Transl Med (Sunnyvale); 2016 Dec; 6(4):. PubMed ID: 28932625 [TBL] [Abstract][Full Text] [Related]
95. Endothelium-derived vasoactive substances. National Institutes of Child Health and Human Development Conference. September 24-25, 1990, Alexandria, Virginia. Proceedings. Semin Perinatol; 1991 Feb; 15(1):1-93. PubMed ID: 2063223 [No Abstract] [Full Text] [Related]
96. Estrogen and vascular function. White RE Vascul Pharmacol; 2002 Feb; 38(2):73-80. PubMed ID: 12379953 [TBL] [Abstract][Full Text] [Related]
97. Exploring the Role of Endothelial Cell Resilience in Cardiovascular Health and Disease. Gao Y; Galis ZS Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):179-185. PubMed ID: 33086867 [TBL] [Abstract][Full Text] [Related]
99. [The function of the vascular wall and drug action]. Chekman IS; Kazak LI Lik Sprava; 1993; (10-12):3-8. PubMed ID: 8030302 [No Abstract] [Full Text] [Related]
100. Latest evidence in endothelium-derived hyperpolarizing factor research. Tsutsui M; Ohya Y; Sugahara K Circ J; 2012; 76(7):1599-600. PubMed ID: 22664724 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]